In addition, there is growing evidence that combining mTOR inhibitors with chemotherapeutic agents (e.g., cisplatin, etc.)could have additional benefits [36,37,38,39], especially in breast cancers, which are principal models in our experiments. This evidence concerns the gene MTOR and breast carcinoma.